Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
JBIO Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Jade Biosciences, Inc.NASDAQ: JBIO
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow of -$24.08M in Q1 FY2026
Q1 FY2026 free cash flow was -$24.08M. Trailing-twelve-month free cash flow was -$116.59M. Over 3 fiscal years it compounded at +34.1% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly free cash flow holds near -$24.08M or moves back toward the trailing-twelve-month quarterly average of -$29.15M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (94.89M) USD
- Year-over-year change
- -33.3%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (94.89M) | -33.3% |
| FY2024 | 2024-12-31 | (71.2M) | -25.1% |
| FY2023 | 2023-12-31 | (56.92M) | -44.8% |
| FY2022 | 2022-12-31 | (39.32M) | -42.6% |
| FY2021 | 2021-12-31 | (27.58M) | — |
Free Cash Flow vs competitors
How JBIO compares with its peers on the latest reported figures
- JBIO's LTM Mar 2026 free cash flow of $116.59M is the 5th largest of the 9 companies compared; the peer median is $105.95M.
- Over three fiscal years its annual growth of +34.1% compares with a peer median of +40.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $339.06M | +81.8% | +52.9% | — | |
| LTM Mar 2026 | $224.15M | +60.0% | +51.9% | — | |
| LTM Mar 2026 | $150.99M | +11.6% | +60.9% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $143.01M | +13.4% | — | — |
| LTM Mar 2026 | $116.59M | — | +34.1% | — | |
| LTM Mar 2026 | $68.89M | +26.2% | +29.9% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $57.66M | +45.8% | +40.0% | — |
| LTM Mar 2026 | $52.27M | +8.5% | -11.6% | 624.8% | |
| LTM Mar 2026 | $15.52M | +23.8% | +10.8% | — | |
| Peer median (excluding JBIO) | $105.95M | +25.0% | +40.0% | 624.8% | |
Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (22.96M) | (51.51M) | (75.52M) | (69.63M) | (127.41M) |
| Depreciation & Amortization | 15K | 68K | 96K | 282K | 26K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (6.51M) | 7.76M | 9.8M | (11.17M) | (8.2M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 609K | 1.37M | (164K) | (2.17M) | 361K |
| Other Working Capital | (7.12M) | 6.39M | 9.96M | (9M) | (8.56M) |
| Other Non-Cash Items | 2.06M | 4.57M | 8.85M | 9.32M | 40.89M |
| Operating Cash Flow | (27.4M) | (39.12M) | (56.78M) | (71.2M) | (94.69M) |
| Capital Expenditures | (181K) | (195K) | (142K) | 0 | (196K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (113.25M) | (147.62M) | (123.98M) | (19.68M) | (261.19M) |
| Sales of Investments | 0 | 154.74M | 136M | 75.71M | 14.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (31K) |
| Investing Cash Flow | (113.43M) | 6.93M | 11.88M | 56.03M | (247.01M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.46M | 396K | 46M | 25.43M | 360.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 156K |
| Financing Cash Flow | 190.46M | 396K | 46M | 25.43M | 360.77M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (52.82M) |
| Net Change in Cash | 49.62M | (31.8M) | 1.09M | 10.26M | 54.69M |
| Free Cash Flow | (27.58M) | (39.32M) | (56.92M) | (71.2M) | (94.89M) |
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.